Amniox Medical, a developer of restorative therapies processed from amniotic membrane and umbilical cord, has been awarded American Podiatric Medical Association (APMA) approval for its NEOX wound matrix and CLARIX regenerative matrix product lines.
Amniox Medical general manager Aaron Smith said: "We are very proud to have our entire product offering recognized by APMA.
"We know that APMA performs a rigorous review of any product under consideration for its Seal of Approval and are honored by their recognition of the safety, quality and extensive scientific evidence supporting our products."
Amniox Medical provides human tissue matrix composed of both amniotic membrane and umbilical cord.
The company’s amniotic membrane/umbilical cord matrix includes key proteins, cytokines and growth factors that have been shown to modulate inflammation and promote regeneration of normal tissue.
The company uses its proprietary cryopreservation technology, CryoTek, for preserving the natural biological and structural integrity of these tissues.